The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01B | Antimetabolites | |
| 4 | L01BA | Folic acid analogues | |
| 5 | L01BA01 | Methotrexate |
| Active Ingredient | Description | |
|---|---|---|
| Methotrexate |
Methotrexate (4-amino-10-methylfolic acid) is a folic acid antagonist which inhibits the reduction of folic acid and increase of tissue cells. Methotrexate enters the cell through an active transport mechanism of reduced folates. As a result of polyglutamation of methotrexate caused by the folylpolyglutamylate enzyme, the duration of the cytotoxic effect of the drug substance in the cell increases. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| JYLAMVO Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
| METHOTREXATE Solution for Injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| METHOTREXATE Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| METOJECT PEN Solution for injection in pre-filled pen | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
